Antivirals to prepare for surges in influenza cases: an economic evaluation of baloxavir marboxil for the Netherlands.
Eur J Health Econ
; 2024 Mar 14.
Article
em En
| MEDLINE
| ID: mdl-38483666
ABSTRACT
OBJECTIVES:
We perform a cost-effectiveness analysis (CEA) and budget impact analysis (BIA) of baloxavir marboxil compared to current care in the Netherlands for patients at risk of influenza-related complications, including patients with comorbidities and the elderly.METHODS:
In the CEA, a decision tree model was developed to assess the cost-effectiveness of baloxavir marboxil for a cohort of 52-year-olds from a societal perspective. A lifetime horizon was taken by incorporating the quality-adjusted life expectancy. The BIA included different epidemiological scenarios, estimating different plausible epidemiological scenarios for seasonal influenza considering the whole Dutch population with an increased risk of influenza complications.RESULTS:
The base-case ICER was estimated to be 8,300 per QALY. At the willingness-to-pay threshold of 20,000 per QALY, the probability of being cost effective was 58%. The base-case expected budget impact was 5.7 million on average per year, ranging from 1.5 million to 10.5 million based on the severity of the influenza epidemic and vaccine effectiveness.CONCLUSION:
In the Netherlands, baloxavir is a cost-effective treatment option for seasonal influenza, with a base-case ICER of 8,300 per QALY for the population aged 60 years and over and patients at high risk of influenza-related complications. For a large part, this ICER is driven by the reduction of the illness duration of influenza and productivity gains in the working population.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
En
Revista:
Eur J Health Econ
Assunto da revista:
SAUDE PUBLICA
/
SERVICOS DE SAUDE
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Holanda